SITC Resource Library

Presentation slides and video from the 2025 Advances in Cancer Immunotherapy^™ (ACI) Series: A Focus on Toxicity Management were presented virtually on March 7, 2025.

Program Organizers

• Marianne Davies, DNP, ACNP, AOCNP, FAAN – Smilow Cancer Hospital at Yale 
• Jordan McPherson, PharmD, MS, BCOP – University of Utah
  
• Alexa Meara, MD – The Ohio State University

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Program Learning Objectives

• Identify appropriate clinical management of common immune-related adverse events resulting from cancer immunotherapy treatments, including immune checkpoint inhibitors and cell therapies.

• Outline best practices for multidisciplinary management of patients receiving cancer immunotherapy treatment.

• Describe management approaches for difficult or refractory immune-related adverse events.

You can view the program agenda here.

Please note on-demand recordings are not available for continuing education credits.